-
Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test
Orbit Genomics was awarded a two-year $2MM Direct to Phase II SBIR Grant from NIH/NCI to develop the second-generation of our lung cancer test, OrbiSeq-L. OrbiSeq-L, is a simple blood test that diagnoses lung cancer in patients that have low-dose CT scans with indeterminate pulmonary nodules, IPNs. Every year, 2.5-3 million Americans have low-dose CT…
-
AI-based Medical Device Company Imidex and Orbit Genomics Form Strategic Relationship to Explore the Detection of Lung Cancer in Early Stages
https://www.prnewswire.com/news-releases/ai-based-medical-device-company-imidex-and-precision-genomix-company-orbit-genomics-form-strategic-relationship-to-explore-the-detection-of-lung-cancer-in-early-stages-302229700.html?tc=eml_cleartime
-
Orbit Genomics Celebrates Graduation From The Cancer X Accelerator Program
Orbit Genomics is proud to attend the graduation of the CancerX Accelerator’s inaugural cohort. We were selected from over 100 startup applicants to participate in this year’s program which included months of mentorship, hands-on learning at the Moffit Cancer Center, and many professional sessions with Champions. We look forward to continue strengthening the relationships with…